LY294002

目录号:S1105 别名: SF 1101, NSC 697286

LY294002 Chemical Structure

Molecular Weight(MW): 307.34

LY294002 是首个合成的已知抑制PI3Kα/δ/β的小分子,在无细胞测定中IC50分别为 0.5 μM/0.57 μM/0.97 μM;在溶液中比在Wortmannin中稳定,也能够阻断自噬体的形成。它不仅能够结合class I PI3Ks和其他PI3K相关的激酶,还能够结合一些与PI3K家族无关的新型靶点。

规格 价格 库存 购买数量  
RMB 1570.11 现货
RMB 1188.16 现货
RMB 2196.01 现货
RMB 6298.74 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户购买Selleck的此次产品后发表的文献73篇:

客户使用该产品的15个实验数据:

  • Type I IFNs induce ISG expression in a serine phosphorylation-independent manner. Cells were treated with kinase inhibitors (SB203580, rottlerin, Ly294002, PD98059, and SP600125) before stimulation with IFN-a and IFN-b for 6 hours. Cell lysates were used in western blotting and probed for serine phosphorylation.The relative amounts of pSTAT1 S727 in (up-graph) were quantied and normalized to an untreated control (below-graph).

    Hepatology 2014 59(4), 1262-72. LY294002 purchased from Selleck.

    different signal-inhibitory profile by applying 120 nmol/L BGT226, 20 μmol/L LY294002, or 100 nmol/L rapamycin in FaDu cells.

    Clin Cancer Res 2011 17, 7116-7126. LY294002 purchased from Selleck.

  • Stimulation response of p37d-expressing cells. (c) Western blot of 5 min serum stimulated HEK-293 cells stably expressing p37d, p110d or control, with the presence of inhibitors as indicated at the top.

    Oncogene 2012 31, 3277–3286. LY294002 purchased from Selleck.

    Immunofluorescence and flow cytometric analyses of the translocation of ABCG2 in MCF-7 FLV1000 cells before and after treatment with the PI3K inhibitor LY294002. Confocal microscopy of MCF-7 FLV1000 cells after a 16-h treatment with 2 uM or 4 uM of LY294002 was performed as described in Figure.

    Br J Pharmacol 2013 70(5), 1137-51. LY294002 purchased from Selleck.

  • SCC61 or Detroit 562 xenografted tumors respond to treatment by PI3K inhibitor, LY294002 alone, or in combination with gefitinib. % tumor growth is shown. By two-way ANOVA, the effect of treatment and time is considered significant;

    Mol Oncol 2013 7, 359-68. LY294002 purchased from Selleck.

    Inhibition of EGFR and PI3K/AKT pathway has additive effects in SCCHN cell lines with constitutively active PIK3CA mutations, while removing negative regulation of PI3K/AKT pathway increases resistance in sensitive SCCHN cell line. A, results from MTT assays on cells treated with PI3K inhibitor, LY294002, and gefitinib.

    Mol Oncol 2013 7, 359-68. LY294002 purchased from Selleck.

  • Lyn-PI3K-BTK signaling is required for the inhibitory effect of anti-CD180 on the activation of IFN-α signaling. (a and b) Isolated murine splenic B220+ B cells were pretreated with dasatinib (5 μM), a Lyn inhibitor; LY294002 (5 μM), a PI3K inhibitor; ibturinib (1 μM), a BTK inhibitor; enzastaurin (1 μM), a PKC β inhibitor; U0126 (3 μM), an ERK inhibitor; SP600126 (2 μM), a JNK inhibitor or SB20358 (1 μM), a p38 inhibitor for 1 h, followed by stimulation with anti-CD180 antibody (0.2 μg/mL) or mouse IFN-α (1000 U/mL) for 4 h. qPCR analysis of the expression of IFIT1 (a) and MX1 (b). (c) Isolated murine splenic B220+ B cells were pretreated with dasatinib (5 μM), LY294002 (5 μM), and ibturinib (1 μM) for 1 h, followed by stimulation with anti-CD180 antibody (0.2 μg mL−1) or mouse IFN-α (1000 U mL−1) for 40 min. Western blot analysis of the phosphorylation level of STAT-2. The data shown represent the mean values of three independent experiments, and the error bars represent the SEM. *p < 0.05, **p < 0.01, ***p < 0.001, as determined by ANOVA; ns denotes p > 0.05.

    Cell Mol Immunol, 2017, 14(2):192-202. LY294002 purchased from Selleck.

    The effects of GLP-1R siRNA and LY294002 on neurological score at 24 hours after subarachnoid hemorrhage (SAH) in Ex-4 treated rats.

    Neuropharmacology, 2018, 128:142-151. LY294002 purchased from Selleck.

  • Comparative effects of inhibitors by immunofluorescence microscopy study. Confluent HC11 cells were grown on poly-L-lysine-coated glass coverslips (immunofluorescence) and on plastic plates (biochemical control) and then treated with inhibitors according to the standard procedure. Upper part: the biochemical action of the inhibitors was tested to validate the immunofluorescence results. Cellular proteins were analyzed by SDS-PAGE and the immunoblots were successively probed with anti-ADRP, anti-β-casein, and anti- β-actin antibodies and their respective HRP-conjugated secondary antibodies. Each experimental condition was performed in duplicate. Lower part: cells were fixed, permeabilized and subjected to immunofluorescence microscopy using antiserum against ADRP and TRITC-conjugated secondary antibody (red).

    Biochim Biophys Acta 2012 1823(5), 987-96. LY294002 purchased from Selleck.

    Comparative effects of wortmannin and LY294002 on ADRP and β -casein synthesis. Con fluent HC11 cells were treated according to the standard procedure in the absence or presence of 4 ng/ml EGF either with or without 100 nM wortmannin or 50μM LY294002. Cellular proteins were analyzed by SDS-PAGE and immunoblot successively probed with anti-ADRP, anti-β-casein, anti-β -actin antibodies and their respective HRP-conjugated secondary antibodies. ECL signals were quantified by densitometry and normalized to β-actin. Each experimental condition was performed in triplicate. Percentages of inhibition for both inhibitor and hormonal treatments are indicated in the text.

    Biochim Biophys Acta 2012 1823(5), 987-96. LY294002 purchased from Selleck.

  • Inhibition of PI3K, ERK and mTOR prevents the activation of S6K1 and S6 induced by suppression of PKD1 activity. A549 cells were incubated in the absence (-) or presence of either 5 uM Kb or 5 uM Kb and 20 uM LY294002 or 5 uM Kb and 10 uM BKM120 (as indicated) for 1 h prior to stimulation of cells with 50 nM PMA for 30 min and 1 h.

    Int J Biochem Cell Biol 2015 60, 34-42. LY294002 purchased from Selleck.

    IGF1 increases apical fibronectin in late stage blastocysts. Representative confocal images of blastocysts stained for fibronectin (Green) and DAPI (Blue). Day 5 blastocysts were cultured in SS medium for 24 (A and B), 48 (C and D) or 72 h (E-H) in the absence (A, C and E) or presence (B, D and F) of 10 ng/ml IGF1 or in the presence of a PI3 Kinase inhibitor (5 uM LY294002 + 10 ng/ml IGF1) (G) or in the presence of 10 ng/ml IGF1, attached to a coverslip (H). Scale bars represent 20 mm. Red line indicates location of coverslip. Arrow indicates location of the inner cell mass (ICM). The following total number of blastocysts were analysed, from at least 3 experimental repeats in each treatment; 24 in the SS group (24 h), 21 in SS plus IGF1 (24 h), 26 in SS (48 h), 30 in SS plus IGF1 (48 h), 40 in SS (72 h), 59 in SS plus IGF1 (72 h), 13 in SS plus IGF1 + LY294002 (48 h) and 15 blastocysts were analysed that were attached to a coverslip (72 h).

    Hum Reprod 2015 30(2), 284-98. LY294002 purchased from Selleck.

  • PTEN transfection or inhibition of the PI3K-AKT and IGF-1R signaling pathways increases the trastuzumab sensitivity of NCI-N87/TR cells. After treating the cells with a PI3K inhibitor (LY294002), the expression of AKT and P-AKT proteins was assessed by Western blotting. Tubulin expression indicated equal loading. All gels run under the same experimental conditions and the experiments were repeated 3 times. The representative images were cropped and shown. Control: cells without any treatment.

    Sci Rep 2015 5, 11634. LY294002 purchased from Selleck.

    We treated all of drugs in T47D which has a PI3KCA H1044R mutation with the concentration shown below for 1 hour and performed western blot analysis using antibodies to phospho-AKT(SERINE 472), and total AKT.

     

     

    2010 Saraswati Sukumar of Johns Hopkins University School of Medicine. LY294002 purchased from Selleck.

  • T47Dcells were pretreated with 100 ng/ml EGF for 20 min and then treated with the indicated concentrations of LY294002 for 24 hours.

     

     

    2010 Dr. Zhang of Tianjin Medical University. LY294002 purchased from Selleck.

产品安全说明书

PI3K抑制剂选择性比较

生物活性

产品描述 LY294002 是首个合成的已知抑制PI3Kα/δ/β的小分子,在无细胞测定中IC50分别为 0.5 μM/0.57 μM/0.97 μM;在溶液中比在Wortmannin中稳定,也能够阻断自噬体的形成。它不仅能够结合class I PI3Ks和其他PI3K相关的激酶,还能够结合一些与PI3K家族无关的新型靶点。
特性 LY294002是选择性的, 可渗透细胞的特定PI3K抑制剂,可作用于酶的ATP结合位点,且抑制自体吞噬的螯合作用。
靶点
p110α [1]
(Cell-free assay)
p110δ [1]
(Cell-free assay)
p110β [1]
(Cell-free assay)
DNA-PK [6]
(Cell-free)
DNA-PK [6]
(Cell-free assay)
0.5 μM 0.57 μM 0.97 μM 1.4 μM 1.4 μM
体外研究

LY294002是一种非特异性抑制剂,除了class I PI3Ks,它同样还能抑制其他类型PI3Ks、mTOR、DNA-PK以及其他蛋白激酶,如CK2和Pim-1[5]。LY294002使Akt/PKB失活,因此抑制细胞增殖和诱导细胞凋亡。 LY294002作用于结肠癌细胞系,使磷酸化Akt (Ser473)的表达下降, 明显抑制生长和诱导凋亡。[2] LY294002作用于肿瘤细胞,诱导明显的核固缩和减少细胞质体积。因此,在体外,LY294002明显抑制卵巢癌细胞增殖。LY294002诱导细胞停在G1期,导致几乎全部的黑色素瘤细胞增殖被抑制,部分MG-63 (骨肉瘤细胞系)增殖被抑制。LY294002作用于细胞周期的效果可用于研究PI3K激活通路和癌细胞周期之间关系。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MDA-MB-231 cells MY\D[YxtKGmwdnHzbY9vKGG|c3H5 Mk\VNlQhcA>? MYPJcohq[mm2aX;uJI9nKGWyaYTo[Yxq[WxiZ4Lve5RpKG[jY4Tvdk1qdmS3Y3XkJINmdGxibXnndoF1cW:wIH;mJIh2dWGwIF3ERU1OSi1{M{GgZ4VtdHNicILlMYlv[3WkYYTl[EBnd3JiMkSgbJJ{KGK7IHPlcIwhcW64YYPpc44h[XO|YYmsJGlEPTB;MD6zPEDPxE1w MViyNlgxPDFyOB?=
Sf21 cells MlzQSpVv[3Srb36gZZN{[Xl? MUjJcohq[mm2aX;uJI9nKG2xdYPlJJdqdGRidInw[UBRUTONYXzwbIEh\XiycnXzd4VlKGmwIGPmNlEh[2WubIOgZ48u\XiycnXzd4lv\yCQLYTldo1qdmGuIFjpd{11[WepZXSgbJVu[W5icEi1ZUB2e2mwZzDMMYFteGijLYDoc5NxcGG2aXT5cIlvd3OrdH;sJJN2[nO2cnH0[UBjgSCWTFOgZoF{\WRicHjvd5Bpd3JiaX3h[4lv\yxiSVO1NF0xNjVizszN NHLmTJAzOjV{ME[zNC=>
Sf21 cells M2S1UmZ2dmO2aX;uJIF{e2G7 NFzzbIJKdmirYnn0bY9vKG:oIH3veZNmKHKnY3;tZolv[W62IGDJN2tidHCqYTDlfJBz\XO|ZXSgbY4h[mGldXzveolzfXNvaX7m[YN1\WRiU3[yNUBk\WyuczygTWM2OD1yLkWg{txONg>? MWexPVc1QDJ4OR?=
Sf9 cells MWDGcJVwemW|Y3XueEBxd2yjcnn6ZZRqd25iYYPzZZk> Mli1TY5pcWKrdHnvckBw\iCqdX3hckBRUTONYXzwbIEh\XiycnXzd4VlKGmwIGPmPUBk\WyuczDifUBndHWxcnXzZ4VvfCCyb3zhdol7[XSrb36gZZN{[XluIFnDOVA:OC53NTFOwG0v NYq3b|RXOjFzMkG2N|E>
THP1 cells M1rkWmZ2dmO2aX;uJIF{e2G7 M{S0SGlvcGmkaYTpc44hd2ZiU1PGNU1qdmS3Y3XkJHBMSi:Da4SgdIhwe3Cqb4L5cIF1cW:wIHnuJHRJWDFiY3XscJMtKEmFNUC9NU4xOSEQvF2u M3j5UVE3Pzh7N{Sy
human PC3 cells NWfGWGJMTnWwY4Tpc44h[XO|YYm= NWrURlBWOzBibXnu MW\Jcohq[mm2aX;uJI9nKFCLM1ugbY4hcHWvYX6gVGM{KGOnbHzzJIF{e2W|c3XkJIF{KGSnY4LlZZNmKGmwIFHLWEBxcG:|cHjvdplt[XSrb36gZZQhe2W{aX7lJFQ4OyCjZoTldkA{OCCvaX7zJIJ6KEWOSWPBMEBKSzVyPUGuN:69VS5? M2POPFI{PDFyMEC1
HeLa (human carcinoma) cells. MmezSpVv[3Srb36gZZN{[Xl? M2mxWWlvKH[rdILvJIlvcGmkaYTpc44hd2ZiRF7BMYRmeGWwZHXueEBxem:2ZXnuJItqdmG|ZTjEUmEuWEtrIH\yc40hUGWOYTCobJVu[W5iY3HyZ4lvd22jKTDj[YxteyxiSVO1NF0yNjRizszNMi=> Mnz0NVU3PTh6N{C=
THP1 cells NXLF[INbTnWwY4Tpc44h[XO|YYm= NXHEW5ZlUW6qaXLpeIlwdiCxZjDNR3AyNWmwZIXj[YQhWEuEL1HreEBxcG:|cHjvdplt[XSrb36gbY4hXEiSMTDj[YxteyxiSVO1NF0yNjZ3IN88UU4> MonYNVY4QDl5NEK=
HeLa cells NFLZcJRHfW6ldHnvckBie3OjeR?= NH3NS|dKdmirYnn0bY9vKG:oIH3UU3IheHKxdHXpckBqe2:uYYTl[EBnem:vIFjlUIEh[2WubIOsJGlEPTB;Mj61JO69VS5? M2PqdlE2PjV6OEew
human MCF7 cells MmTrR5l1d3SxeHnjxsBie3OjeR?= MVLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIlvKHC{ZYPlcoNmKG:oIEKwJO69VSClaHzvdo9yfWmwZTDifUBUWkJiYYPzZZktKEeLNUC9Nk43OyEQvF2u NH7BTo0yQDZ7MUi5OC=>
HeLa cells NYO0[nN2TnWwY4Tpc44h[XO|YYm= NVKzSWZ7UW6qaXLpeIlwdiCxZjDBXE04PTB|IHLpcoRqdmdidH:gdoVkd22kaX7hcpQhWGytMzDlfJBz\XO|ZXSgbY4hUGWOYTDj[YxteyCkeTDX[ZN1\XKwIHLsc5QtKEmFNU2zJO69VS5? M13LOVE4OTN3MkS4
human MCF7 cells NXnvOJhCS3m2b4TvfIlkyqCjc4PhfS=> MXPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIlvKHC{ZYPlcoNmKG:oIEGwJJVOKGOqbH;yc5F2cW6nIHL5JHNTSiCjc4PhfUwhT0l3ME2zMlA5KM7:TT6= M17Nb|E5PjlzOEm0
human MCF7 cells NX7zWohGS3m2b4TvfIlkyqCjc4PhfS=> MUfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIJ6KFOUQjDhd5NigSxiR1m9N{4yPiEQvF2u MVexPFY6OTh7NB?=
human MDA-MB-231 cells MV\DfZRwfG:6aXRCpIF{e2G7 Ml33R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUKzNUBk\WyuczDpckBxemW|ZX7j[UBw\iB{MDFOwG0h[2iub4LvdZVqdmViYomgV3JDKGG|c3H5MEBIUT1|LkOyJO69VS5? M4jhZ|E5PjlzOEm0
human MDA-MB-231 cells MlLHR5l1d3SxeHnjxsBie3OjeR?= M1PufmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj2yN|Eh[2WubIOgbY4heHKnc3XuZ4Uhd2ZiMUCgeW0h[2iub4LvdZVqdmViYomgV3JDKGG|c3H5MEBIUTVyPUSuN|Uh|ryPLh?= MYGxPFY6OTh7NB?=
human MDA-MB-468 cells MXfDfZRwfG:6aXRCpIF{e2G7 NXXjeGl5S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVQ3QCClZXzsd{BqdiCycnXz[Y5k\SCxZjCyNEB2VSClaHzvdo9yfWmwZTDifUBUWkJiYYPzZZnwxIxiSVO1NF01Njd4IN88UU4> NH3QR4IyQDZ7MUi5OC=>
human HCT116 cells NFfsbndIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MoHiOFghcA>? M1rYfWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGhEXDFzNjDj[YxteyCxdnXy[ZhxemW|c3nu[{BRUTONYXzwbIEhUDFyNEfSJI12fGGwdDDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTVwMzFOwG0> M4nUb|IzOjF{N{Kx
human HCT116 cells NGDOfnVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MonZOFghcA>? MmeyS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gTGNVOTF4IHPlcIx{KGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEmFNUC9OU45KM7:TT6= NUPCdGhTOjJ{MUK3NlE>
HeLa cells MoCwRolv\GmwZzDh[oZqdmm2eTDhd5NigQ>? NVO2dZV{SmmwZHnu[{Bi\m[rbnn0fUBnd3JiUFmzMYtqdmG|ZTDpd49t[XSnZDDmdo9uKEinTHGgZ4VtdHNuIFvpQVYh|ryP NEjTbWkyPTZ3OEi3NC=>
human HCT116 cells M3rpdGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHPWNVU1QCCq NVXGVHZyT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hUEOWMUG2JINmdGy|IH;2[ZJmgHC{ZYPzbY5oKFCLM1vhcJBp[SCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVYvPyEQvF2u MkWzNlIzOTJ5MkG=
MDA-MB-231 cells M4iwcGN6fG:2b4jpZ:Kh[XO|YYm= M3HJ[WN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj2yN|Eh[2WubIOgZpkhW1KEIHHzd4F6NCCJSUWwQVYvPzFizszNMi=> NF7ycFkyQDZ7MUi5OC=>
Sf9 cells Mly4SpVv[3Srb36gZZN{[Xl? NIPaT|FKdmirYnn0bY9vKG:oIFPLNkBmgHC{ZYPz[YQhcW5iU3[5JINmdGy|LDDJR|UxRTZwOTFOwG0v NHW1RowyQDN{MUexOi=>
human U87MG cells NWXqOWcyTnWwY4Tpc44h[XO|YYm= NYTGPWdVUW6qaXLpeIlwdiCxZjDHV2s{NWKndHGgbY4hcHWvYX6gWVg4VUdiY3XscJMh[nliRVzJV2EtKEmFNUC9PE4yKM7:TT6= MV2xPFM1PTZyOR?=
human MDA-MB-468 cells NH;te29EgXSxdH;4bYPDqGG|c3H5 MXXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvNE[4JINmdGy|IHnuJJBz\XOnbnPlJI9nKDFyIIXNJINpdG:{b4H1bY5mKGK7IGPSRkBie3OjeTygS2k2OD16LkKg{txONg>? MXqxPFY6OTh7NB?=
human A375 cells MUPQdo9tcW[ncnH0bY9vKGG|c3H5 MlnJOFYhcA>? NVLOTHE2SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBN|c2KGOnbHzzJIFnfGW{IES2JIhzeyxiSVO1NF05NjRizszNMi=> MW[xO|A1QTJ2OB?=
human A375 cells NWftSFVkWHKxbHnm[ZJifGmxbjDhd5NigQ>? M3jZWGlvcGmkaYTpc44hd2Zic3XyeY0ucW6mdXPl[EBxem:uaX\ldoF1cW:wIH;mJIh2dWGwIFGzO|Uh[2WubIOsJGlEPTB;OD60JO69VS5? M3vZSlE4PjBzN{O5
human HL60 cells NVy4U3RKS3m2b4TvfIlkyqCjc4PhfS=> MYS3NkBp MYnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIUFYxKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;OT65OEDPxE1w NWGybI5jOjJ2OEC4OVE>
mouse Raw264 macrophage NXLEVZh5TnWwY4Tpc44h[XO|YYm= NHrEO4JKdmirYnn0bY9vKG:oIFO1ZU1u\WSrYYTl[EBRU0JxQXv0JJBpd3OyaH;yfYxifGmxbjDpckBud3W|ZTDSZZczPjRibXHjdo9xcGGpZTygTWM2OD1zMDFOwG0v MV[xOlc5QTd2Mh?=
Sf9 cells MoTWSpVv[3Srb36gZZN{[Xl? M1G2NmlvcGmkaYTpc44hd2ZiSHnzMZRi\2enZDDic5ZqdmViUFmzT{BmgHC{ZYPz[YQhcW5iU3[5JINmdGy|LDDJR|UxRTFyIN88UU4> NUX4[mlQOTB7OUizOVE>
human MDA-MB-468 cells M4DIe2N6fG:2b4jpZ:Kh[XO|YYm= NW\6U3Y2S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVQ3QCClZXzsd{BjgSCVUlKgZZN{[XluIFnDOVA:OTBwNDFOwG0v M33mdVE5PjlzOEm0
human PC3 cell NIjTNmJRem:uaX\ldoF1cW:wIHHzd4F6 NEe2[Gw4OiCq NGrWNXFKdmirYnn0bY9vKG:oIHj1cYFvKFCFMzDj[YxtKHC{b3zp[oVz[XSrb36gZYZ1\XJiN{KgbJJ{KGK7IIPw[YN1em:yaH;0c41mfHKrYzDhcoFtgXOrczygTWM2OD1zMj6xJO69VS5? M16yflI{PDFyMEC1
human HL60 cells MV3Qdo9tcW[ncnH0bY9vKGG|c3H5 NH\YZ5A4OiCq NFjUeoRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjMOlAh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDhZpNwemKjbnPlJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MUiuOFMh|ryPLh?= NHvIN|gzPTZ7M{e4Oy=>
human BT474 cell NFfiSGVRem:uaX\ldoF1cW:wIHHzd4F6 NGTVRXY4OiCq MlLQTY5pcWKrdHnvckBw\iCqdX3hckBDXDR5NDDj[YxtKHC{b3zp[oVz[XSrb36gZYZ1\XJiN{KgbJJ{KGK7IIPw[YN1em:yaH;0c41mfHKrYzDhcoFtgXOrc,-8kEBKSzVyPUKwMlch|ryPLh?= MnPPNlM1OTByMEW=
THP1 cells M{Xk[GZ2dmO2aX;uJIF{e2G7 M2P5[2lvcGmkaYTpc44hd2ZiTVPQNU1qdmS3Y3XkJINp\W2xdHH4bZMhd2ZiVFjQNUBk\WyuczygTWM2OD1|NzFOwG0v NYHGPHNnOTZ5OEm3OFI>
human 184B5 cells MlXPR5l1d3SxeHnjxsBie3OjeR?= NGnmSlBEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckAyQDSENTDj[YxteyCkeTDTVmIh[XO|YYmsJGdKPTB;M{muN|ch|ryPLh?= NFnkdXEyQDZ7MUi5OC=>
human KB cells NFjGeFNEgXSxdH;4bYPDqGG|c3H5 MmHBO|IhcA>? Ml34R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gT2Ih[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD12ND63OkDPxE1w MXKyNVk1PTJ3MB?=
mouse RAW264.7 cells MX\GeY5kfGmxbjDhd5NigQ>? MoraNlUh|ryP NYW0WFN4OjBiaB?= NFLjUVlKdmirYnn0bY9vKG:oIGDJN2swSUuWIHnuJI1wfXOnIGLBW|I3PC55IHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhVFCVLXnu[JVk\WRiaV7PV{Bxem:2ZXnuJIV5eHKnc4Ppc44h[XRiMkWg{txOKGGodHXyJFIxKGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN? M4nCd|I1Ojl7NkG2
human A2780 cells NHzTOZdCeG:ydH;zbZMh[XO|YYm= M2nRRVIh|ryP NF7BNHYyOiCq MlG4TY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDjbZNxdGG2aX6tdoV{cXO2YX70JIh2dWGwIFGyO|gxKGOnbHzzJIF{e2W|c3XkJIF{KGSnY4LlZZNmKGmwIIDoc5NxcG:{eXzheIVlKEGtdDDs[ZZmdCCjdDCyJJVOKGGodHXyJFEzKGi{czDifUBqdW23bn;icI91KGGwYXz5d4l{Ng>? MVWxO|Y5PDBzOB?=
human SW480 cells Mnv5SpVv[3Srb36gZZN{[Xl? MXSyNEDPxE1? M4TMb|I1KGh? MVXE[YNz\WG|ZTDpckB{fXK4aY\pckBmgHC{ZYPzbY9vKGmwIHj1cYFvKFOZNEiwJINmdGy|IHH0JFIxKHWPIHHmeIVzKDJ2IHjyd{BjgSCrbX31co9jdG:2IHHuZYx6e2m| MmryNVc1PzJ7NkK=
mouse mast cells MUPGeY5kfGmxbjDhd5NigQ>? NXjiXVl{OjBizszN MlLxTY5pcWKrdHnvckBw\iCVQ1[tbY5lfWOnZDDQT2IwSWu2IIDoc5NxcG:{eXzheIlwdiCrbjDtc5V{\SCvYYP0JINmdGy|IHH0JFIxKM7:TR?= NGezZ2IyPjd6OUe0Ni=>
human BJ cells NYnMe2dDTnWwY4Tpc44h[XO|YYm= NVz6c3FTOjVizszN M2jSflIhcA>? M{nJUGlvcGmkaYTpc44hd2ZiUFmzT{B{cWewYXzpcochcW5iUFTHSk1{fGmvdXzheIVlKHOncoXtJJN1[XK4ZXSgbJVu[W5iQlqgZ4VtdHNidILhcpNn\WO2ZXSge4l1cCCybHHzcYllKEWJRmCvVGgh\G:vYXnuJI9nKEGtdDDhd5Nme3OnZDDhd{B{fXCycnXzd4lwdiCxZjDQTE1GT0[SIILl[Il{fHKrYoX0bY9vKHSxIIDsZZNu[SCvZX3idoFv\SCjdDCyOUB2VSC2cnXheIVlKDJiaILzJIJm\m:{ZTDQSGdHKGOqYXzs[Y5o\SCkeTDjc45nd2OjbDDtbYNzd3Olb4D5 MnLxNVY4PjdyOEW=
human IGROV1 cells MWDGeY5kfGmxbjDhd5NigQ>? MVWyOE81QCCq MVHJcohq[mm2aX;uJI9nKFCLM1uvRYt1KGmwIHj1cYFvKEmJUl;WNUBk\WyuczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiCyaH;zdIhwenmuYYTl[EBCU1RibHX2[Ywh[XRiMTD0c{A2KHSrbXXzJGlEPTBiYX\0[ZIhOjRidH:gOFghcHK|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>? MoO5NlEzOTZzNUG=
human IGROV1 cells MmHtSpVv[3Srb36gZZN{[Xl? NFmybXQzPC92ODDo NXzpRZZ2UW6qaXLpeIlwdiCxZjDQTVNMN0GtdDDpckBpfW2jbjDJS3JQXjFiY3XscJMh[XO|ZYPz[YQh[XNiZHXjdoVie2ViaX6gZ5lkdGmwIFSxJIxmfmWuIHH0JFEhfG9iNTD0bY1meyCLQ{WwJIFnfGW{IEK0JJRwKDR6IHjyd{BjgSCZZYP0[ZJvKGKub4SgZY5idHm|aYO= NHOyeJgzOTJzNkG1NS=>
rat RBL2H3 cells NWnPOXZPTnWwY4Tpc44h[XO|YYm= MnOwTY5pcWKrdHnvckBw\iCDMkOxPFcucW6mdXPl[EBl\We{YX71cIF1cW:wIHnuJJJifCCUQlyyTFMh[2WubIO= Moj6NVg{Ojh5MU[=
human BJ cells MkfRSpVv[3Srb36gZZN{[Xl? M4XNZVI2KM7:TR?= MWWyJIg> NVnvb3VLSWO2aY\heIlwdiCxZjDBb5QheGixc4Doc5J6dGG2aX;uJIF1KFSqckOwPEBqdiCSRFfGMZN1cW23bHH0[YQhe2W{dX2gd5Rien[nZDDoeY1idiCESjDj[YxteyCjdDCyOUB2VSC2cnXheIVlKDJiaILzJIJm\m:{ZTDQSGdHKGOqYXzs[Y5o\SCkeTDpcY12dm:kbH;0eIlv\w>? NFzlPGEyPjd4N{C4OS=>
human HCT116 cells NUfRVodITnWwY4Tpc44h[XO|YYm= MV:xNEDPxE1? NEO1[YYyOCCvaX6= MXHJcohq[mm2aX;uJI9nKFCLM1vhcJBp[SCrbjDoeY1idiCKQ2SxNVYh[2WubIOgeZNqdmdiW{OyVH1CXFBiYYSgNVAhfU1iYX\0[ZIhOTBibXnudy=> NIHnclUzOjJzMkeyNS=>
human HCT116 cells MVPGeY5kfGmxbjDhd5NigQ>? M1LMTlExKM7:TR?= M2PPXVExKG2rbh?= MlvaTY5pcWKrdHnvckBw\iCSSUPLZYxxcGFiSEGwOFdTKG23dHHueEBqdiCqdX3hckBJS1RzMU[gZ4VtdHNidYPpcochYzN{UG3BWHAh[XRiMUCgeW0h[W[2ZYKgNVAhdWmwcx?= NIP0XowzOjJzMkeyNS=>
human HCT116 cells NFfwcWdHfW6ldHnvckBie3OjeR?= NHnJem4yOCEQvF2= NF7xfopKdmirYnn0bY9vKG:oIGDJN2tidHCqYTDpckBpfW2jbjDIR3QyOTZiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBCc3RiU3XyOFc{KHCqb4PwbI9zgWyjdHnvckBifCBzMDD1UUBjgSCrbX31co9jdG:2IHHuZYx6e2m| NHzrfo8zOjJzMkeyNS=>
human HCT116 cells MmW1SpVv[3Srb36gZZN{[Xl? M4rvOVExKM7:TR?= MWPJcohq[mm2aX;uJI9nKFCLM1vhcJBp[SCKMUC0O3IhdXW2YX70JIlvKGi3bXHuJGhEXDFzNjDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKEGtdDDT[ZI1PzNicHjvd5Bpd3K7bHH0bY9vKGG2IEGwJJVOKGK7IHntcZVvd2Kub4SgZY5idHm|aYO= M4T1UlIzOjF{N{Kx
human PC3 cells NYPRU41LTnWwY4Tpc44h[XO|YYm= MVS1NEDPxE1? M{jiflghcA>? NFfjVnZKdmS3Y4Tpc44hd2ZicEKxJJBzd3SnaX6g[ZhxemW|c3nvckBqdiCqdX3hckBRSzNiY3XscJMh[XRiNUCgeW0hcW6ldXLheIVlKG[xcjC4JIhzeyCkeTDX[ZN1\XKwIHLsc5R1cW6pIILlcIF1cX[nIITvJJVvfHKnYYTl[EBkd262cn;s M3z5elIzQTl6NEey
human LNCAP cells MUjGeY5kfGmxbjDhd5NigQ>? M2rkOVAvOS1|MDFOwG0> M3LxWlMxKG2rbh?= NFq2fIxKdmirYnn0bY9vKG:oIFHreEBxcG:|cHjvdplt[XSrb36gbY4hcHWvYX6gUG5ESVBiY3XscJMh[XRiMD6xJJRwKDNyIIXNJIFnfGW{IEOwJI1qdnNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{ NF7CcYMzOjh|MkOxOi=>
human LNCAP cells NHPpenpHfW6ldHnvckBie3OjeR?= M1XZWlAvOS1|MDFOwG0> MoCwNlQhcA>? MXrEc5dvemWpdXzheIlwdiCxZjDzeZJ3cX[rbjDlfJBz\XO|aX;uJIlvKGi3bXHuJGxPS0GSIHPlcIx{KGG2IECuNUB1dyB|MDD1UUBi\nSncjCyOEBpenNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{ NWrpN2tlOjJ6M{KzNVY>
HUVEC NVLteHczTnWwY4Tpc44h[XO|YYm= MlfiNVAuOjVizszN M{LySFE3KGh? MofrTY5pcWKrdHnvckBw\iCWTl\hcJBp[S2|dHnteYxifGWmIFnDRW0uOSCvUl7BJIV5eHKnc4Ppc44hcW5iSGXWSWMh[XRiMUCgeI8hOjVidV2gdJJmfHKnYYTl[EBnd3JiMU[gbJJ{KGKnZn;y[UBVVk[jbIDoZUBkcGGubHXu[4UhdWWjc4Xy[YQh[W[2ZYKgOkBpenNiYomgVnQuWEOUIHHuZYx6e2m| NFHoRlAzOjB{NkSxNC=>
HUVEC NGW3fHpHfW6ldHnvckBie3OjeR?= MmLUNVAuOjVizszN MXqzNEBucW5? M4n5eGlvcGmkaYTpc44hd2ZiVF7GZYxxcGFvc4TpcZVt[XSnZDDoeY1idiCLQ1HNMVEheHKxbX;0[ZIh[WO2aY\peJkh\XiycnXzd4VlKGmwIFjVWmVEKGG|c3Xzd4VlKGG|IHLleIEu\2GuYXP0c5Nq\GG|ZTDhZ5Rqfmm2eTDheEAyOCC2bzCyOUB2VSCycnX0doVifGWmIH\vdkA{OCCvaX7zJIJm\m:{ZTDUUmZidHCqYTDjbIFtdGWwZ3WgcYVie3W{ZXSgZYZ1\XJiNTDodpMh[nlibIXjbYZmemG|ZTDy[ZBwenSncjDn[Y5mKGG|c3H5 M{XCfVIzODJ4NEGw
human H1299 cells NW[3SIxnTnWwY4Tpc44h[XO|YYm= M{\mUFAvOS1|MDFOwG0> MnTpNlQhcA>? M1\YU2Rwf25icnXneYxifGmxbjDv[kBkUUGSMjDlfJBz\XO|aX;uJIlvKGi3bXHuJGgyOjl7IHPlcIx{KGG2IECuNUB1dyB|MDD1UUBi\nSncjCyOEBpenNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{ NUTUdIpWOjJ4MkKwOlk>
human H1299 cells NWDtc2YzTnWwY4Tpc44h[XO|YYm= Mm\JNE4yNTNyIN88US=> NWXhVmVlOjRiaB?= M1nxcWRwf25icnXneYxifGmxbjDv[kBkUUGSMjDlfJBz\XO|aX;uJIlvKGi3bXHuJGgyOjl7IHPlcIx{KGG2IECuNUB1dyB|MDD1UUBi\nSncjCyOEBpenNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{KGmwIIDy[ZNmdmOnIH;mJFExOCC3Zz;tcEBVWkGLTDDhcoQhWEl|SzDpcohq[mm2b4KgUHkzQTRyMEK= NVzwSVFXOjJ4MkKwOlk>
human H1299 cells NHG0cplHfW6ldHnvckBie3OjeR?= NV;mNnRIOC5zLUOwJO69VQ>? NX;ub4FGOjRiaB?= NYTmWJRoUW6mdXP0bY9vKG:oIFTSOUBmgHC{ZYPzbY9vKGmwIHj1cYFvKEhzMkm5JINmdGy|IHH0JFAvOSC2bzCzNEB2VSCjZoTldkAzPCCqcoOgZpkhX2W|dHXyckBjdG:2IHHuZYx6e2m| M{\MW|IzPjJ{ME[5
human H1299 cells Ml;NSpVv[3Srb36gZZN{[Xl? NGLUOmcxNjFvM{Cg{txO MWSyOEBp MV7JcoR2[3Srb36gc4YhUk6NLX3l[IlifGWmIFPIU3Ah\XiycnXzd4lwdiCrbjDoeY1idiCKMUK5PUBk\WyuczDheEAxNjFidH:gN|AhfU1iYX\0[ZIhOjRiaILzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?= MV6yNlYzOjB4OR?=
HEK293 cells NUTYNYRPTnWwY4Tpc44h[XO|YYm= MnXNNU42KGh? M4L0c2Rqe3CuYXPlcYVvfCCxZjDbN2heVFOGIH\yc40hcHWvYX6gOWhVPiC{ZXPldJRweiCneIDy[ZN{\WRiaX6gTGVMOjl|IHPlcIx{KGGodHXyJFEvPSCqcoOgZpkhdGmzdXnkJJNkcW62aXzsZZRqd25iY3;1cpRqdmd? M3\qTFIzPTN5MUWz
human U251HRE cells NVvYZmMxTnWwY4Tpc44h[XO|YYm= NWW0bHk6UW6qaXLpeIlwdiCxZjDofZBwgGmjLXnu[JVk\WRiSFnGNUBi[3SrdnH0bY9vKGmwIHj1cYFvKFV{NUHIVmUh[2WubIOgZpkh[2WubDDiZZNm\CC{ZYDvdpRmeiCpZX7lJIF{e2G7 MUKxPFUxOTZyMR?=
human HCT116 cells NYD1WYo2TnWwY4Tpc44h[XO|YYm= NGnNeVMyOCEQvF2= NV3SXod5UW6qaXLpeIlwdiCxZjDBb5Qh\XiycnXzd4lwdiCrbjDoeY1idiCKQ2SxNVYh[2WubIOgZZQhOTBidV2gZpkhcW2vdX7vZoxwfCCjbnHsfZNqew>? MnO0NlIzOTJ5MkG=
Sf9 cells M{O0NYZtfW:{ZYPj[Y51KHCxbHHybZpifGmxbjDhd5NigQ>? NWfvc2UxUW6qaXLpeIlwdiCxZjDoeY1idiCSSUPL[4FudWFiZYjwdoV{e2WmIHnuJHNnQSClZXzsd{BjgSCobIXvdoV{[2WwdDDwc4xiemm8YYTpc44h[XO|YYm= M{fEblIyOTJzNkOx
human HCT116 cells M2X0enBzd2yrZnXyZZRqd25iYYPzZZk> M1zMU|czKGh? M{O5OWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPUNVE3KGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gZYJ{d3KkYX7j[UBi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUWxMlgzKM7:TT6= MYOyOVY6Ozd6Nx?=
human HCT116 cells MoTNR5l1d3SxeHnjxsBie3OjeR?= MonWO|IhcA>? M{L1ZmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhEXDFzNjDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVU3NjBzIN88UU4> MYCyNVk1PTJ3MB?=
human PC3 cells MlLOR5l1d3SxeHnjxsBie3OjeR?= NVPhVVNrPzJiaB?= MkDqR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVGM{KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;NkGuN|Uh|ryPLh?= MXuyNlQ5ODh3MR?=
human HuH7 cells M1q1VXBzd2yrZnXyZZRqd25iYYPzZZk> MXu3NkBp NEPiPYpCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFj1TFch[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDhZpNwemKjbnPlJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;NkeuNVgh|ryPLh?= NXzvc3NWOjV4OUO3PFc>
human A549 cells NEDBcZdRem:uaX\ldoF1cW:wIHHzd4F6 M3vybVczKGh? M2\QfGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUW0PUBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHHid49z[mGwY3WgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD16Mj6zNkDPxE1w MYeyOVY6Ozd6Nx?=
human A549 cells NGm5bm9EgXSxdH;4bYPDqGG|c3H5 NVPvdVA{PzJiaB?= M1HWcWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfS=> MoPrNlI1QDB6NUG=
human PC3 cells M3vFU3Bzd2yrZnXyZZRqd25iYYPzZZk> M{jqTFI2KM7:TR?= M4TqW|EzOCCq NFHRVnRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGDDN{Bk\WyuczDheEAzPSC3TTDh[pRmeiBzMkCgbJJ{KGK7IF3UWEBie3OjeTDy[YxifGm4ZTD0c{BFVVOR NWK5WI9DOTZ4OECxOVk>
human H460 cells M1PYcWZ2dmO2aX;uJIF{e2G7 MV6zNEDPxE1? MVHJcohq[mm2aX;uJI9nKFCLM1ugbY4hcHWvYX6gTFQ3OCClZXzsd{Bie3Onc4Pl[EBieyCDa4SgdIhwe3Cqb4L5cIF1cW:wIHH0JHNmeiB2N{OgeZAhfG9iM{CgeW0> M1\PclE5PTBzNkCx
human IGROV1 cells NVzOXZkzTnWwY4Tpc44h[XO|YYm= NVzDUFFROjRiaB?= M{LhSWNmdGxiY4njcIUh[XK{ZYP0JIlvKGi3bXHuJGlIWk:YMTDj[YxteyCjc4Pld5Nm\CCjczDhZ4N2dXWuYYTpc44h[XRiR{GgdIhie2ViYYSgNUBnd2ymIFnDOVAh[W[2ZYKgNlQhcHK|IHL5JIZtd3diY4n0c41mfHK7 NWrwepU{OjF{MU[xOVE>
human IGROV1 cells M1js[2Z2dmO2aX;uJIF{e2G7 NGL4[HczPCCq MX7D[YxtKGO7Y3zlJIFzemW|dDDpckBpfW2jbjDJS3JQXjFiY3XscJMh[XO|ZYPz[YQh[XNiYXPjeY12dGG2aX;uJIF1KEdzIIDoZZNmKGG2IEWg[o9t\CCLQ{WwJIFnfGW{IEK0JIhzeyCkeTDmcI94KGO7dH;t[ZRzgQ>? M1LHeVIyOjF4MUWx
human H4 cells NWHnfVRDTnWwY4Tpc44h[XO|YYm= MoLsNkBp MmfhSIVkemWjc3WgbY4hTlmYRT3SSnAsKH[nc3njcIUhcW62ZX7zbZR6KHCncjDj[YxtKGmwIHj1cYFvKEh2IHPlcIx{KGGodHXyJFIhcHK|IILlcIF1cX[nIITvJINwdnS{b3y= NInhTYYyQDB{NEW4OC=>
human MGC803 cells M3fUSWZ2dmO2aX;uJIF{e2G7 NW\jdHpsOjVizszN MYO0PEBp M1zMXGNmdGxiY4njcIUh[XK{ZYP0JIlvKGi3bXHuJG1ISzhyMzDj[YxteyCjc4Pld5Nm\CCjczDhZ4N2dXWuYYTpc44h[XRiR{KvUUBxcGG|ZTDheEAzPSC3TTDh[pRmeiB2ODDodpMhfXOrbnegdJJweGmmaYXtJIlw\GmmZTDzeIFqdmmwZzDh[pRmeiB2ODDodpMh[nliZnzve{BkgXSxbXX0[ZIhemWuYYTpeoUhfG9iY3;ueJJwdA>? NUX3TmNkOjRzMUm4Olk>

... Click to View More Cell Line Experimental Data

体内研究 体内,LY294002也抑制肿瘤生长和诱导凋亡,尤其作用于LoVo肿瘤, 因此作用于鼠癌性腹膜炎模型具有明显药效。[2] LY294002明显抑制卵巢癌生长和腹水形成。[3]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[4]

+ 展开

激酶实验:

使用重组酶和1 μM ATP,通过辐射实验测定LY294002对PI3K的抑制效果。室温下(24oC)进行激酶反应1小时,然后加入PBS终止反应。通过剂量反应曲线测定IC50值。通过激酶选择性筛选来抑制CK2和GSK3β。加入10 μM ATP,测定LY294002作用于一组激酶的效果。
细胞实验:

[2]

+ 展开
  • Cell lines: 结肠癌细胞系: DLD-1, LoVo, HCT15, 和Colo205
  • Concentrations: 0-50 μM
  • Incubation Time: 0-48小时
  • Method:

    1×105个细胞(每孔100 μL)接种在96孔板上。加入LY294002,重复加三次,在37oC下培养0-48小时。处理后, 10 μL Premix WST-1 加到每孔中,然后在37oC下温育60分钟,然后用微型计数板在450nm处测定吸光值。


    (Only for Reference)
动物实验:

[3]

+ 展开
  • Animal Models: 腹腔注射OVCAR-3细胞的无胸腺裸鼠(5-7周大)
  • Formulation: 溶解在DMSO和0.25 ml PBS中
  • Dosages: 0-100 mg/kg
  • Administration: 每天腹腔注射,持续3周
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 36 mg/mL (117.13 mM)
Ethanol 21 mg/mL (68.32 mM)
Water Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
4% DMSO+30% PEG 300+5% Tween 80+ddH2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 307.34
化学式

C19H17NO3

CAS号 154447-36-6
稳定性 powder
in solvent
别名 SF 1101, NSC 697286

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    I want to buy a inhibitor that can inactivates Akt/PI3K. I notice the protocol of LY294002 (catalog no. s1105) says it will inactivates Akt/PKB. Is LY294002 available for Akt/PI3K inhibition?

  • 回答:

    LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively. It can inhibit PI3K/AKT. PKB is the alternative name of AKT.

  • 问题 2:

    What is the suggested formulation of this compound for mouse injection(i.p.)?

  • 回答:

    It can be dissolved in 4% DMSO/30% PEG 300/5% Tween 80/ddH2O at 5 mg/ml clearly, and the concentration of DMSO is safe for in vivo experiments.

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

相关PI3K产品

Tags: 购买LY294002 | LY294002供应商 | 采购LY294002 | LY294002价格 | LY294002生产 | 订购LY294002 | LY294002代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID